By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Alimentary Pharmacology. According to news reporting from Baltimore, Maryland, by NewsRx journalists, research stated, "Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent condition. Emerging evidence suggests that vitamin D may play a role in the pathogenesis of NAFLD."
The news correspondents obtained a quote from the research from Johns Hopkins University, "To review systematically the association between vitamin D levels, measured as serum 25-hydroxy vitamin D [25(OH) D], and NAFLD. We used PubMed and EMBASE databases to identify all studies that assessed the association between vitamin D and NAFLD up until 22 April 2013, without language restrictions. We included studies that compared vitamin D levels between NAFLD cases and controls and also those that compared the odds of vitamin D deficiency by NAFLD status. Pooled standardised differences and odds ratios were calculated using an inverse variance method. Seventeen cross-sectional and case-control studies have evaluated the association between vitamin D and NAFLD. NAFLD was diagnosed using biopsy (4 studies), ultrasound or CT (10 studies) and liver enzymes (3 studies). Nine studies provided data for a quantitative meta-analysis. Compared to controls, NAFLD patients had 0.36 ng/mL (95% CI: 0.32, 0.40 ng/mL) lower levels of 25(OH) D and were 1.26 times more likely to be vitamin D deficient (OR 1.26, 95% CI: 1.17, 1.35). NAFLD patients have decreased serum 25(OH) D concentrations, suggesting that vitamin D may play a role in the development of NAFLD. The directionality of this association cannot be determined from cross-sectional studies."
According to the news reporters, the research concluded: "Demonstration of a causal role of hypovitaminosis D in NAFLD development in future studies could have important therapeutic implications."
For more information on this research see: Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 2013;38(3):246-254. Alimentary Pharmacology & Therapeutics can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Alimentary Pharmacology & Therapeutics - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2036)
Our news journalists report that additional information may be obtained by contacting M. Eliades, Johns Hopkins University, Welch Center Prevent Epidemiol & Clin Res, Baltimore, MD, United States (see also Alimentary Pharmacology).
Keywords for this news article include: Maryland, Baltimore, Alcoholism, United States, Fatty Liver Disease, Alcoholic Fatty Liver, Alimentary Pharmacology, North and Central America, Digestive System Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.